Back to top
more

Fortress Biotech (FBIO)

(Real Time Quote from BATS)

$1.97 USD

1.97
44,619

+0.10 (5.35%)

Updated May 28, 2024 11:11 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for FBIO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Fortress Biotech, Inc. [FBIO]

Reports for Purchase

Showing records 281 - 300 ( 315 total )

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 281

04/18/2019

Company Report

Pages: 8

Mustang Shines in NEJM for XSCID Promise

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 282

03/18/2019

Company Report

Pages: 8

2018 Results; A Plethora of Subsidiary News Should Support Shares; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 283

02/20/2019

Daily Note

Pages: 6

Mustang Sets up a One-Two Punch for Glioblastoma; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 284

02/13/2019

Company Report

Pages: 9

Portfolio Model Working, So Should Stock; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 285

08/10/2018

Company Report

Pages: 7

2Q18 Results; Subsidiaries Have Been Busy; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 286

05/21/2018

Company Report

Pages: 6

Avenue Nails First Phase 3; Second to Start in 3Q18

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 287

05/11/2018

Company Report

Pages: 6

1Q18 Results; Important Subsidiary Catalysts Soon; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 288

03/27/2018

Daily Note

Pages: 6

Additional Phase 1b Analysis Further Highlights CAEL-101 Efficacy as Asset Is Ready to Go Pivotal

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 289

03/16/2018

Company Report

Pages: 6

2017 Results; Cranking on More and More Pistons; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 290

01/02/2018

Company Report

Pages: 5

Avenue Pivotal Program Expands and Data Not Too Far Off; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 291

12/12/2017

Company Report

Pages: 15

Caelum and Mustang Subsidiaries Shine at ASH; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 50.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 292

12/05/2017

Company Report

Pages: 6

Busy Times at Fortress; Important Updates at ASH Shortly; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 293

09/27/2017

Daily Note

Pages: 5

Dulling the Pain Is Avenue''s Game; Tramadol Phase 3 Gets Rolling; 2Q18 Data Not Too Far Off

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 294

08/10/2017

Company Report

Pages: 6

2Q17 Results; Several Subsidiaries Gaining Momentum

Provider: Rodman & Renshaw, Co.

Price: 25.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 295

08/10/2017

Company Report

Pages: 6

2Q17 Results; Several Subsidiaries Gaining Momentum

Provider: H.C. Wainwright & Co., Inc.

Price: 25.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 296

07/11/2017

Company Report

Pages: 26

We are initiating coverage with a Buy rating and $11 price target.

Provider: Rodman & Renshaw, Co.

Price: 75.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 297

07/11/2017

Company Report

Pages: 26

A Growing Portfolio Play in One Fell Swoop; Initiating Coverage at Buy, $11 PT

Provider: H.C. Wainwright & Co., Inc.

Price: 75.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 298

05/25/2017

Company Report

Pages: 4

We are dropping coverage to reallocate our research resources.

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 299

05/24/2017

Daily Note

Pages: 3

Corrected - Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Fortress Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 300

12/19/2016

Company Report

Pages: 4

We are transferring coverage of FBIO to Sa''ar Yaniv, due to the departure of the covering analyst and placing shares Under Review

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party